삼성제약

001360KOSPI의약품 제조업

58.5 / 100

Reference Date: 2026-07-24

Financial Score23.0 / 40

News Sentiment19.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly down 1.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung Pharmaceutical operates in pharmaceutical manufacturing and sales, biopharma, and health food sectors, distributing a wide range of products including specialty and over-the-counter drugs. The company is advancing clinical trials for pancreatic cancer treatment GV1001 and Alzheimer's disease, with revenue reaching 460.7 billion KRW in 2025.

Number of Employees

87people

Average Salary

66.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

10.68Industry Average 11.235.0Point

In line with industry avg

PBR

1.02Industry Average 0.812.5Point

Higher than industry avg (caution)

ROE

10.18Industry Average 4.017.0Point

2.5x industry avg (excellent)

Debt Ratio

3.37Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼5.4% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼2.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -10.9% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 4Neutral 1Negative 0Average Sentiment Score 78

Neutral
[임상 업데이트] 앱클론, AT101 2상 대상자 모집 완료
앱클론의 AT101 임상 2상 대상자 모집 완료 소식은 제약바이오 분야 내에서의 긍정적인 신호이지만, 삼성제약과 직접적인 연관성이 없어 중립적 평가.
Positive
삼성제약, 진행성핵상마비 국내 3상 계획서 제출
삼성제약의 PSP 치료제 GV1001의 국내 임상 3상 진행 발표로 긍정적인 시장 반응 예상.
Positive
치료제 없는 희귀 뇌질환…삼성제약, 3상 도전
삼성제약의 희귀 뇌질환 치료제 GV1001의 한국 3상 임상 진입 소식으로 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 1,314Won52-week high 2,21052-week low 1,243

1-month return3.0Point

1m -1.65% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0